(Q43860373)

27 November 2017

title

Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption (English)

1 reference

27 November 2017

6

1 reference

27 November 2017

0 references

A Laroni

1

1 reference

27 November 2017

D Brogi

2

1 reference

27 November 2017

V Milesi

3

1 reference

27 November 2017

L Abate

4

1 reference

27 November 2017

A Uccelli

5

1 reference

27 November 2017

publication date

26 November 2012

1 reference

Multiple Sclerosis Journal

27 November 2017

published in

1 reference

27 November 2017

volume

19

1 reference

27 November 2017

issue

9

1 reference

27 November 2017

page(s)

1236-1237

1 reference

Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal.

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458512468498

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512468498

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512468498

Central nervous system recruitment of effector memory CD8+ T lymphocytes during neuroinflammation is dependent on α4 integrin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512468498

21 January 2018

Identifiers

DOI

10.1177/1352458512468498

1 reference

27 November 2017

1 reference